skip to main content
Idioma:
Refinado por: Base de dados/Biblioteca: DOAJ Directory of Open Access Journals remover Nome da Publicação: Esmo Open remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
158TiP Neoadjuvant abemaciclib and giredestrant trial in patients with ER-positive, HER2-negative early breast cancer (GIM31-Neo-AGILE trial)
158TiP Neoadjuvant abemaciclib and giredestrant trial in patients with ER-positive, HER2-negative early breast cancer (GIM31-Neo-AGILE trial)
Material Type:
Artigo 		Adicionar ao Meu Espaço

158TiP Neoadjuvant abemaciclib and giredestrant trial in patients with ER-positive, HER2-negative early breast cancer (GIM31-Neo-AGILE trial)

von Arx, C. ; Calabrese, A. ; Caputo, R. ; Di Lauro, V. ; Pensabene, M. ; Buono, G. ; Fabi, A. ; Cognetti, F. ; Guarneri, V. ; Puglisi, F. ; Vigneri, P. ; Del Mastro, L. ; Arpino, G. ; De Laurentiis, M.

ESMO open, 2024-05, Vol.9, p.103145, Article 103145 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
2
164P Circulating cytokines levels as predictive biomarkers in pleural mesothelioma: Preliminary data from a prospective translational study
164P Circulating cytokines levels as predictive biomarkers in pleural mesothelioma: Preliminary data from a prospective translational study
Material Type:
Artigo 		Adicionar ao Meu Espaço

164P Circulating cytokines levels as predictive biomarkers in pleural mesothelioma: Preliminary data from a prospective translational study

Scattolin, D. ; Urso, L. ; Cavallari, I. ; Ferro, A. ; Maso, A. Dal ; Frega, S. ; Bonanno, L. ; Guarneri, V. ; Pasello, G.

ESMO open, 2024-03, Vol.9, p.102740, Article 102740 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
3
1MO HER2DX assay and survival outcomes: An individual-patient level meta-analysis of 2,031 patients with HER2-positive breast cancer
1MO HER2DX assay and survival outcomes: An individual-patient level meta-analysis of 2,031 patients with HER2-positive breast cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

1MO HER2DX assay and survival outcomes: An individual-patient level meta-analysis of 2,031 patients with HER2-positive breast cancer

Javierre, G. Villacampa ; Cortés, J. ; García, J.M. Pérez ; Cussac, A. Llombart ; Tarantino, P. ; Conte, P.F. ; Mancino, M. ; Guarneri, V. ; Dieci, M.V. ; Waks, A. ; Brasó-Maristany, F. ; Pascual, T. ; Griguolo, G. ; Gonzalez, P. Villagrasa ; Parker, J. ; Vivancos, A. ; Perou, C.M. ; Brunet, L. Pare ; Prat, A. ; Tolaney, S.M.

ESMO open, 2024-05, Vol.9, p.103011, Article 103011 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
4
1MO Tumor immune microenvironment in ER-negative vs ER-low, HER2-neg breast cancer
1MO Tumor immune microenvironment in ER-negative vs ER-low, HER2-neg breast cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

1MO Tumor immune microenvironment in ER-negative vs ER-low, HER2-neg breast cancer

Massa, D. ; Vernieri, C. ; Nicolè, L. ; Criscitiello, C. ; Boissiere, F. ; Guiu, S. ; Bobrie, A. ; Griguolo, G. ; Miglietta, F. ; Vingiani, A. ; Lobefaro, R. ; Salimbeni, B. Taurelli ; Pruneri, G. ; Fassan, M. ; Curigliano, G. ; Guarneri, V. ; Jacot, W. ; Dieci, M.V.

ESMO open, 2023-05, Vol.8 (1), p.101225, Article 101225 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
5
206P Liver kinase B1 expression is associated with improved overall survival and decreased CD8+ tumor infiltrating lymphocytes in small cell lung cancer
206P Liver kinase B1 expression is associated with improved overall survival and decreased CD8+ tumor infiltrating lymphocytes in small cell lung cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

206P Liver kinase B1 expression is associated with improved overall survival and decreased CD8+ tumor infiltrating lymphocytes in small cell lung cancer

Maso, A. Dal ; Ferrarini, F. ; Esposito, G. ; Pezzuto, F. ; Zulato, E. ; Bao, L.C. ; De Nuzzo, M. ; Ferro, A. ; Frega, S. ; Pasello, G. ; Calabrese, F. ; Fassan, M. ; Guarneri, V. ; Indraccolo, S. ; Bonanno, L.

ESMO open, 2024-03, Vol.9, p.102779, Article 102779 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
6
225P Platinum-based chemotherapy and PARP Inhibitors for BRCA mutated metastatic breast cancer (LATER-BC): Retrospective multicentre analysis of post-progression treatments
225P Platinum-based chemotherapy and PARP Inhibitors for BRCA mutated metastatic breast cancer (LATER-BC): Retrospective multicentre analysis of post-progression treatments
Material Type:
Artigo 		Adicionar ao Meu Espaço

225P Platinum-based chemotherapy and PARP Inhibitors for BRCA mutated metastatic breast cancer (LATER-BC): Retrospective multicentre analysis of post-progression treatments

Valenza, C. ; Trapani, D. ; Sposetti, C. ; Bielo, L. Boscolo ; Marra, A. ; Giarratano, T. ; Cortesi, L. ; Moscetti, L. ; Pistelli, M. ; Berardi, R. ; Zambelli, A. ; Guarneri, V. ; Vernieri, C. ; Curigliano, G.

ESMO open, 2023-05, Vol.8 (1), p.101414, Article 101414 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
7
33P Breast cancer brain metastases present a suppressed immune microenvironment enriched in macrophagic components as compared to paired primary tumors
33P Breast cancer brain metastases present a suppressed immune microenvironment enriched in macrophagic components as compared to paired primary tumors
Material Type:
Artigo 		Adicionar ao Meu Espaço

33P Breast cancer brain metastases present a suppressed immune microenvironment enriched in macrophagic components as compared to paired primary tumors

Griguolo, G. ; Tosi, A. ; Bottosso, M. ; Bauchet, L. ; Zanghi, F. ; Pellegrini, V. ; Miglietta, F. ; Rigau, V. ; Guarascio, M.C. ; Fassan, M. ; Jacot, W. ; Rosato, A. ; Guarneri, V. ; Darlix, A. ; Dieci, M.V.

ESMO open, 2024-05, Vol.9, p.103041, Article 103041 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
8
50P Circulating cytokines to predict pCR to neoadjuvant chemotherapy and nivolumab for ER+/HER2- BC: Analysis of the phase II GIADA trial
50P Circulating cytokines to predict pCR to neoadjuvant chemotherapy and nivolumab for ER+/HER2- BC: Analysis of the phase II GIADA trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

50P Circulating cytokines to predict pCR to neoadjuvant chemotherapy and nivolumab for ER+/HER2- BC: Analysis of the phase II GIADA trial

Dieci, M.V. ; Tosi, A. ; Bicciato, S. ; Bisagni, G. ; Musolino, A. ; Spazzapan, S. ; Vernaci, G.M. ; Griguolo, G. ; Giarratano, T. ; Miglietta, F. ; Urso, L. ; Schiavi, F. ; Pinato, C. ; De Salvo, G. ; Rosato, A. ; Guarneri, V.

ESMO open, 2024-05, Vol.9, p.103057, Article 103057 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
9
57P Prognostic impact of functional domain of BRCA1/2 mutation in platinum-sensitive recurrent epithelial ovarian cancer patients receiving PARP inhibitors
57P Prognostic impact of functional domain of BRCA1/2 mutation in platinum-sensitive recurrent epithelial ovarian cancer patients receiving PARP inhibitors
Material Type:
Artigo 		Adicionar ao Meu Espaço

57P Prognostic impact of functional domain of BRCA1/2 mutation in platinum-sensitive recurrent epithelial ovarian cancer patients receiving PARP inhibitors

Mosimann, F. Stella ; Varano, V. ; Tasca, G. ; Girardi, F. ; Tozzi, R. ; Massa, D. ; Zovato, S. ; Saccardi, C. ; Moserle, L. ; Montagna, M. ; Griguolo, G. ; Guarneri, V.

ESMO open, 2024-06, Vol.9, p.103564, Article 103564 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
10
5P HER2DX risk-score in HER2-positive (HER2+) breast cancer following neoadjuvant and adjuvant anti-HER2-based treatment: An updated survival analysis
5P HER2DX risk-score in HER2-positive (HER2+) breast cancer following neoadjuvant and adjuvant anti-HER2-based treatment: An updated survival analysis
Material Type:
Artigo 		Adicionar ao Meu Espaço

5P HER2DX risk-score in HER2-positive (HER2+) breast cancer following neoadjuvant and adjuvant anti-HER2-based treatment: An updated survival analysis

Saez, O. Martinez ; Brasó-Maristany, F. ; Griguolo, G. ; Brunet, L. Pare ; Dieci, M.V. ; Cortés, J. ; Cussac, A. Llombart ; Villacampa, G. ; Marín-Aguilera, M. ; Rey, M. ; Goberna, G. ; Munoz, M. ; Vivancos, A. ; Gonzalez, P. Villagrasa ; Parker, J. ; Conte, P.F. ; Prat, A. ; Pascual, T. ; Guarneri, V.

ESMO open, 2023-05, Vol.8 (1), p.101229, Article 101229 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.